Aspirin use may decrease type of ovarian cancer, though risks of analgesic use must still be considered

November 7, 2012
Aspirin use may decrease type of ovarian cancer
Credit: Shutterstock

A new study conducted by European researchers in Denmark suggests that regular use of pain relief medications such as aspirin, can lead to a decreased risk of serious ovarian cancer in women. This is important news because despite significant progress in the field of gynaecological cancer treatment during recent decades, the prognosis has remained poor, and many have stressed that preventive strategies are urgently needed.

Ovarian cancer is an aggressive carcinoma that affects the surface of the ovary; it is the deadliest gynaecological malignancy and the fifth leading cause of death by cancer for in developed countries. It is estimated that the age-standardised rates for ovarian in Europe range from 12 per 100 000 women in southern Europe to 17 per 100 000 in northern Europe in 2008. The countries with the highest incidence rates were Latvia and Lithuania (around 19 per 100 000), and the lowest were Cyprus and Portugal (around 7 per 100 000). According to the (CDC), 20 000 women in the United States are diagnosed with ovarian cancer each year, with 90 % of cases occurring in women older than 40 years of age and the greatest number in those 60 years or older.

'Ovarian cancer has a high mortality. Understanding what factors are involved in the development of this disease and investigating preventative interventions for women are vitally important,' said lead author Dr Susanne Kjær with the Danish Cancer Society Research Center. 'Our study examined the role of analgesics in development of ovarian cancer.' Their study was published in Acta Obstetricia et Gynecologica Scandinavica, a journal of the Nordic Federation of Societies of and noted that that non-aspirin non-steroidal (NSAIDs), paracetamol (acetaminophen) or other analgesics did not decrease ovarian .

For their study the researchers used data from the malignant ovarian cancer (MALOVA) study, a population-based, case control study investigating this cancer in Danish women between 1995 and 1999. Previous studies report that Denmark has incidence and mortality rates at 11 and 7 per 100 000 women, respectively. The team analysed data from 756 women with epithelial ovarian cancer, classified by type of glandular tumours (adenocarcinomas); 447 were serous, 138 were mucinous and 171 were other types. A random sample of 1 564 women between the ages of 35 and 79 were drawn from the general population as controls. With their sample in place the team then conducted personal interviews to determine analgesic drug use.

Their findings from these interviews indicate that women taking aspirin on a regular basis decreased their risk of serious ovarian cancer (odds ratio, OR=.60). However, the researchers did not find a decrease in ovarian cancer risk in women who regularly used non-aspirin NSAIDs, acetaminophen or other types of pain relievers.

Dr Kjær concludes, 'Our findings suggest a potential protective effect of analgesic use on ovarian cancer risk, but that benefit should be balanced against adverse effects of pain medication use, such as risk of bleeding and peptic ulcers.' The authors recommend that larger studies, which accurately assess dosage, frequency and duration of pain medications, are necessary to understand the impact of analgesic use on ovarian cancer.

Dr Magnus Westgren from Karolinska University Hospital in Stockholm, Sweden concurs with the study authors in his editorial and comments that strategies for preventing ovarian cancer are imperative. Dr Westgren discusses preventive procedures such as bilateral salingectomy (BSE) - a removal of the fallopian tubes - in women at risk for ovarian cancer.

'If we informed women about the possibility of performing BSE at repeat caesarean section for ovarian cancer prevention, it is likely that many women would opt for this procedure,' writes Dr Westgren. He suggests that gynaecology professionals discuss changing policies and setting up randomised trials to further understand how BSE could reduce risk.

Explore further: Aspirin may decrease risk of aggressive form of ovarian cancer

More information: Ammundsen, H. B., et al., 'Use of analgesic drugs and risk of ovarian cancer: results from a Danish case-control study', Acta Obstetricia et Gynecologica Scandinavica, 2012, 91(9), 1094. doi:10.1111/j.1600-0412.2012.01472.x … /%28ISSN%291600-0412

Related Stories

Aspirin may decrease risk of aggressive form of ovarian cancer

October 9, 2012
New research shows that women who regularly use pain relief medications, particularly aspirin, have a decreased risk of serous ovarian cancer—an aggressive carcinoma affecting the surface of the ovary. The study published ...

Study links endometriosis with increased risk of developing 3 specific types of ovarian cancer

February 21, 2012
Women with a history of endometriosis are significantly more likely to develop three specific types of ovarian cancer (clear cell, endometrioid, and low-grade serous), according to an article published Online First in the ...

Researchers discover antibody that may help detect ovarian cancer in earliest stages

August 16, 2011
Using a new approach to developing biomarkers for the very early detection of ovarian cancer, researchers at Rush University Medical Center have identified a molecule in the bloodstream of infertile women that could one day ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.